Bellerophon Therapeutics Inc. said in a Form 8-K filing that Matthew Holt resigned as a director Dec. 11.
Further, the Bellerophon board elected CEO Fabian Tenenbaum as a director.
Discover more about S&P Global’s offerings
Bellerophon director resigns, CEO joins board
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Essential IR Insights Newsletter - February 2023
Insight Weekly: US bank margins rise; smartphone shipments drop; coal miners book strong sales
Bellerophon Therapeutics Inc. said in a Form 8-K filing that Matthew Holt resigned as a director Dec. 11.
Further, the Bellerophon board elected CEO Fabian Tenenbaum as a director.